|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NEUROREGULATION AND MOTILITY
CURE/Digestive Diseases Research Center and Center for Neurovisceral Sciences and Womens Health, Division of Digestive Diseases, Department of Medicine, University of California and Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California
We characterized the influence of the selective corticotropin-releasing factor 2 (CRF2) receptor agonist human urocortin 2 (Ucn 2), injected intracisternally, on gastric emptying and its mechanism of action compared with intracisternal CRF or urocortin (Ucn 1) in conscious rats. The methylcellulose phenol red solution was gavaged 20 min after peptide injection, and gastric emptying was measured 20 min later. The intracisternal injection of Ucn 2 (0.1 and 1 µg) and Ucn 1 (1 µg) decreased gastric emptying to 37.8 ± 6.9%, 23.1 ± 8.6%, and 21.6 ± 5.9%, respectively, compared with 58.4 ± 3.8% after intracisternal vehicle. At lower doses, Ucn 2 (0.03 µg) and Ucn 1 (0.1 µg) had no effect. The CRF2 antagonist astressin2-B (3 µg ic) antagonized intracisternal Ucn 2 (0.1 µg) and CRF (0.3 µg)-induced inhibition of gastric emptying. Vagotomy enhanced intracisternal Ucn 2 (0.1 or 1 µg)-induced inhibition of gastric emptying compared with sham-operated group, whereas it blocked intracisternal CRF (1 µg) inhibitory action (45.5 ± 8.4% vs. 9.7 ± 9.7%). Sympathetic blockade by bretylium prevented intracisternal and intracerebroventricular Ucn 2-induced delayed gastric emptying, whereas it did not influence intravenous Ucn 2-, intracisternal CRF-, and intracisternal Ucn 1-induced inhibition of gastric emptying. Prazosin abolished the intracisternal Ucn 2 inhibitory effect, whereas yohimbine and propranolol did not. None of the pretreatments modified basal gastric emptying. These data indicate that intracisternal Ucn 2 induced a central CRF2-mediated inhibition of gastric emptying involving sympathetic
1-adrenergic mechanisms independent from the vagus contrasting with the vagal-dependent inhibitory actions of CRF and Ucn 1.
adrenergic receptors; vagus; corticotropin-releasing hormone receptor
This article has been cited by other articles:
![]() |
T. Nemoto, N. Yamauchi, and T. Shibasaki Novel action of pituitary urocortin 2 in the regulation of expression and secretion of gonadotropins J. Endocrinol., April 1, 2009; 201(1): 105 - 114. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kimura, T. Amano, H. Uehara, H. Ariga, T. Ishida, A. Torii, H. Tajiri, K. Matsueda, and S. Yamato Urocortin I is present in the enteric nervous system and exerts an excitatory effect via cholinergic and serotonergic pathways in the rat colon Am J Physiol Gastrointest Liver Physiol, October 1, 2007; 293(4): G903 - G910. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. P. Bakshi, S. M. Newman, S. Smith-Roe, K. A. Jochman, and N. H. Kalin Stimulation of Lateral Septum CRF2 Receptors Promotes Anorexia and Stress-Like Behaviors: Functional Homology to CRF1 Receptors in Basolateral Amygdala J. Neurosci., September 26, 2007; 27(39): 10568 - 10577. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |